Sheldon L. Koenig insider trades

Open-market stock purchases and sales by Sheldon L. Koenig, President and CEO at Esperion Therapeutics, Inc, from SEC Form 4 filings since Jan 31, 2020.

Track record: 50% of 2 scored buys are up 5% or more since purchase, averaging +54%.

Recent trades

DateStockTradeValue
Jul 13, 2026ESPR Esperion Therapeutics, IncSold (not open market)—
Jul 13, 2026ESPR Esperion Therapeutics, IncSold (not open market)$1.3M
Jul 13, 2026ESPR Esperion Therapeutics, IncSold (not open market)$1.1M
Jul 13, 2026ESPR Esperion Therapeutics, IncSold (not open market)$1.6M
Jun 17, 2026ESPR Esperion Therapeutics, IncSold$169K
Mar 17, 2026ESPR Esperion Therapeutics, IncSold$69.5K
Mar 13, 2026ESPR Esperion Therapeutics, IncBought (not open market)—
Mar 13, 2026ESPR Esperion Therapeutics, IncBought (not open market)—
Dec 17, 2025ESPR Esperion Therapeutics, IncSold$177K

Companies traded

  • ESPR Esperion Therapeutics, Inc: 2 buys, 13 sales, last Jul 13, 2026
  • PTLA Portola Pharmaceuticals Inc: other filings, last Jul 2, 2020

Get free alerts when Sheldon L. Koenig files a new trade →